Insider Trading Alert - REGI, GNMK And NSH Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 11, 2015, 93 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,570.00 to $275,612,220.00.

Highlighted Stocks Traded by Insiders:

Renewable Energy Group (REGI) - FREE Research Report

Stone Chad, who is Cfo at Renewable Energy Group, bought 2,000 shares at $8.65 on May 11, 2015. Following this transaction, the Cfo owned 79,536 shares meaning that the stake was boosted by 2.58% with the 2,000-share transaction.

The shares most recently traded at $8.59, down $0.06, or 0.7% since the insider transaction. Historical insider transactions for Renewable Energy Group go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 7,923
  • 12-Week # shares bought: 13,000
  • 12-Week # shares sold: 7,923
  • 24-Week # shares bought: 13,000
  • 24-Week # shares sold: 7,923

The average volume for Renewable Energy Group has been 324,500 shares per day over the past 30 days. Renewable Energy Group has a market cap of $389.9 million and is part of the basic materials sector and energy industry. Shares are down 9.68% year-to-date as of the close of trading on Monday.

Renewable Energy Group, Inc. produces and sells biofuels and renewable chemicals in the United States. It operates through two segments, Biomass-Based Diesel and Services. The company has a P/E ratio of 7.4. Currently, there is 1 analyst who rates Renewable Energy Group a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on REGI - FREE

TheStreet Quant Ratings rates Renewable Energy Group as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full Renewable Energy Group Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

GenMark Diagnostics (GNMK) - FREE Research Report

Chakravarty Ingo, who is SVP, International at GenMark Diagnostics, sold 583 shares at $9.49 on May 11, 2015. Following this transaction, the SVP, International owned 61,132 shares meaning that the stake was reduced by 0.94% with the 583-share transaction.

The shares most recently traded at $9.19, down $0.30, or 3.26% since the insider transaction. Historical insider transactions for GenMark Diagnostics go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 5,942
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 108,440
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 127,415

The average volume for GenMark Diagnostics has been 185,900 shares per day over the past 30 days. GenMark Diagnostics has a market cap of $401.2 million and is part of the health care sector and health services industry. Shares are down 30.05% year-to-date as of the close of trading on Monday.

GenMark Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, sells, and supports instruments and molecular tests based on its proprietary eSensor detection technology in the United States. Currently, there are 5 analysts who rate GenMark Diagnostics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GNMK - FREE

TheStreet Quant Ratings rates GenMark Diagnostics as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and weak operating cash flow. Get the full GenMark Diagnostics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

NuStar GP Holdings (NSH) - FREE Research Report

Greehey William E, who is Director at NuStar GP Holdings, bought 18,701 shares at $37.78 on May 11, 2015. Following this transaction, the Director owned 8.2 million shares meaning that the stake was boosted by 0.23% with the 18,701-share transaction.

The shares most recently traded at $37.70, down $0.08, or 0.22% since the insider transaction. Historical insider transactions for NuStar GP Holdings go as follows:

  • 4-Week # shares bought: 34,383
  • 12-Week # shares bought: 34,383
  • 24-Week # shares bought: 34,383

The average volume for NuStar GP Holdings has been 128,800 shares per day over the past 30 days. NuStar GP Holdings has a market cap of $1.7 billion and is part of the basic materials sector and energy industry. Shares are up 11.71% year-to-date as of the close of trading on Monday.

NuStar GP Holdings, LLC, through its ownership interests in NuStar Energy L.P., engages in the transportation of petroleum products and anhydrous ammonia; terminalling and storage of petroleum products; and marketing of petroleum products. The stock currently has a dividend yield of 5.67%. The company has a P/E ratio of 22.1. Currently, there is 1 analyst who rates NuStar GP Holdings a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NSH - FREE

TheStreet Quant Ratings rates NuStar GP Holdings as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in stock price during the past year and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company's profit margins have been poor overall. Get the full NuStar GP Holdings Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

AMD Rises Above the Competition; Loan Losses Mount for Big Banks -- ICYMI

AMD Rises Above the Competition; Loan Losses Mount for Big Banks -- ICYMI

McKesson Internal Review Clears Senior Management of Wrongdoing on Opioids

McKesson Internal Review Clears Senior Management of Wrongdoing on Opioids

Starbucks Surprises Wall Street With U.S. Sales Up a Paltry 2%

Starbucks Surprises Wall Street With U.S. Sales Up a Paltry 2%

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2